Shares of Molina Healthcare, Inc. (NYSE:MOH) ended Friday session in red amid volatile trading. The shares closed down -0.36 points or -0.63% at $57.01 with 375,849 shares getting traded. Post opening the session at $57.61, the shares hit an intraday low of $56.86 and an intraday high of $57.75 and the price vacillated in this range throughout the day. The company has a market cap of $3.22 billion and the numbers of outstanding shares have been calculated to be 56.80 million shares.
Molina Healthcare, Inc. (MOH) announced that it will report its earnings for the third quarter ended September 30, 2016, after the market closes on Thursday, October 27, 2016. The Company’s management will host a conference call and webcast to discuss the earnings release at 5:00 p.m. Eastern time on the same day.
The number to call for the interactive teleconference is (212) 231-2903. A telephonic replay of the conference call will be available from 7:00 p.m. Eastern time on Thursday, October 27, 2016, through 6:00 p.m. on Friday, October 28, 2016, by dialing (800) 633-8284 and entering confirmation number 21818529.
A live broadcast of Molina Healthcare’s conference call will be available on the Company’s website, molinahealthcare.com. A 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.
Shares of Organovo Holdings Inc (NYSEMKT:ONVO) ended Friday session in red amid volatile trading. The shares closed down -0.20 points or -5.12% at $3.71 with 1.10 million shares getting traded. Post opening the session at $3.92, the shares hit an intraday low of $3.70 and an intraday high of $3.96 and the price vacillated in this range throughout the day. The company has a market cap of $325.24 million and the numbers of outstanding shares have been calculated to be 92.66 million shares.
Organovo Holdings Inc (ONVO) announced its plan to develop 3D bioprinted human liver tissue for direct transplantation to patients. The Company is announcing its program to develop this therapeutic tissue based on the achievement of strong results in preclinical studies in animal models showing engraftment, vascularization and sustained functionality of its bioprinted liver tissue, including stable detection of liver-specific proteins and metabolic enzymes. Organovo expects to pursue this opportunity with a formal preclinical development program.
For patients in need of a liver transplant, no robust alternatives exist. Approximately 17,000 patients are on the U.S. liver transplant waiting list, and only 6,000 liver transplants are performed each year. Organovo plans to develop clinical solutions in two initial areas. First, acute-on-chronic liver failure (“ACLF”) is a recognized and distinct orphan disease entity encompassing an acute deterioration of liver function in patients with liver disease, which affects 150,000 patients annually in the United States. Second, pediatric metabolic liver diseases represent another orphan disease indication where a bioprinted liver tissue patch may show therapeutic benefits. The total addressable market opportunity for these initial indication areas exceeds $3 billion. Assuming development progresses according to its current plan, Organovo intends to submit an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for its therapeutic liver tissue in three to five years. As appropriate, Organovo will pursue breakthrough therapy designation, clinical development outside the United States, and other opportunities to help accelerate time to market.